Global Life Science Ventures — Investing in the life sciences

Global Life Science Ventures (GLSV) is a leading, independent venture capital fund focusing exclusively on the life sciences. GLSV is dedicated to supporting early-stage groups, originating from universities, scientific institutions or industry. The fund may also invest in selected later stage companies, including buy-outs. For this purpose, GLSV provides finance, advice and access to expertise and networks. The group currently advises and manages funds totalling more than € 200 million. With offices in Germany and Switzerland, GLSV acts as one team with a global perspective.

Profile
Team
Investment Practice
Portfolio
FAQ
Download Area
News
Events
Contact Us
Text size

GLSV news

14.01.2010 Global Life Science Ventures: 2009 Review more...

13.02.2009 Global Life Science Ventures: 2008 highlights more...

22.04.2008 GLSV receives 2007 Dyodelta European Life Science Innovation Award "Investor of the Year Award" more...

14.04.2008 April 2008 Teil 20 der Serie: Köpfe der deutschsprachigen Private Equity-Szene, Hanns-Peter Wiese, Venture Capial Magazin 4/2008 more...

17.01.2008 GLSV leads investment in Action Pharma A/S more...

06.12.2007 GLSV invests in Pelikan Technologies more...

02.10.2007 Biotech Investment Barometer Reveals Continued Confidence in Sector
more...

11.05.2007 NeurogesX Launches IPO on NASDAQ more...

29.03.2007 GLSV co-leads Series E investment in Coapt Systems more...

20.12.2006 "10 years' investing in the life sciences" more...

More news

............................................................................................

Portfolio company news

23.06.2010 Santaris Pharma A/S and miRagen Therapeutics, Inc. form strategic alliance to develop microRNA-targeted medicines for the treatment of cardiovascular disease
more...

15.06.2010 Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound more...

07.06.2010 Pieris AG Appoints Chief Scientific Officer more...

07.06.2010 Action Pharma obtains encouraging preliminary results in a phase II clinical trial with AP214 more...

02.06.2010 Nabriva initiates Phase II of pleuromutilin antibiotic BC-3781 more...

26.05.2010 7TM Pharma receives milestone payment from asthma and allergy collaboration more...

30.04.2010 NeurogesX Enters $40 Million Royalty Financing Agreement with Cowen Healthcare Royalty Partners more...

30.04.2010 Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program more...

26.04.2010 Santaris Pharma A/S advances RNA-targeted drug development candidate against PCSK9, an important new target for the treatment of high cholesterol more...

22.04.2010 A potential new treatment for cancer supportive care and gastrointestinal diseases more...

More news